Ezetimibe


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Homozygous familial sitosterolaemia; Hyperlipidaemias 10 mg once daily.
Dosage Details
Oral
Homozygous familial sitosterolaemia, Hyperlipidaemias
Adult: 10 mg once daily.
Child: ≥10 yr Same as adult dose.
Administration
May be taken with or without food.
Special Precautions
Exclude or treat secondary causes of dyslipidaemia prior to initiating therapy. Renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Headache, abdominal pain, diarrhoea, fatigue, chest pain, arthralgia, myalgia, anaphylaxis, erythema multiforme, angioedema, rash, and urticaria. Rarely, raised liver enzymes or hepatitis, pancreatitis, thrombocytopenia, cholelithiasis, cholecystitis, raised creatine kinase, myopathy, and rhabdomyolysis.
MonitoringParameters
Monitor total cholesterol profile prior to therapy and periodically thereafter.
Drug Interactions
Reduced absorption w/ colestyramine. Increased plasma concentrations w/ ciclosporin. Concomitant use w/ oral anticoagulants may result in increased INR.
Action
Description: Ezetimibe localises at the brush border of the small intestine and inhibits absorption of cholesterol via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This results in decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and increased clearance of cholesterol from the blood.
Pharmacokinetics:
Absorption: Rapidly absorbed. Time to peak plasma concentration: 4-12 hr.
Distribution: Plasma protein binding: >90%.
Metabolism: Undergoes extensive conjugation in small intestine and liver to form an active glucuronide metabolite; may also undergo enterohepatic recycling.
Excretion: Via bile in the faeces (approx 78% mainly as unchanged drug); urine (approx 11% mainly as metabolite). Elimination half-life: Approx 22 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store at 25°C. Protect from moisture.
Disclaimer: This information is independently developed by MIMS based on Ezetimibe from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in